Glucagon-like peptide-1 (GLP-1) was first discovered in the 1980s as a regulator of glucose levels. Further research led to the creation of a stabilized GLP-1RA called semaglutide, the active ...

A new GLP-1 weight loss drug called survodutide has shown promising results in a phase 3 clinical trial. The drug, which ...

Researchers have shed valuable light on the complex mechanisms by which a class of psychedelic drugs binds to and activates serotonin receptors to produce potential therapeutic effects in patients ...

Resolution occurred after stopping dulaglutide, no obvious clues to mechanism ...

A new study suggests GLP-1 weight-loss drugs may be able to do more than curb appetite. Here's what researchers found.

GLP‑1 drugs appear to change how much we want to eat, and how strongly food “pulls” on the brain. Newer oral versions may ...

A meta-analysis of 32 studies and 43,618 adults presented at the European Congress on Obesity in Istanbul, Turkey (May 12–15) ...

Activation of the serotonin receptor, 5-HT1A, has been shown to regulate mood and cognition. The receptor is the primary target of buspirone, vilazodone, and gepirone, FDA-approved medications for the ...

A single molecule that tricks its way into fat cells by mimicking a gut hormone, then releases a second drug once inside, has ...

Rendering a drug effective or ineffective in a flash at the appropriate location – this is the focus of research in photopharmacology. The goal is to develop drugs that can be switched on and off with ...